SCHEMBL6008529

SCHEMBL6008529

S=Cn1nnc2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.53
NPC1 O15118 2/20 0.53
SLC9A1 P19634 8/20 0.50
MAPT P10636 2/20 0.50
POLB P06746 1/20 0.50
MAPK1 P28482 1/20 0.50
ATM Q13315 1/20 0.50
KEAP1 Q14145 1/20 0.50
ALDH1A1 P00352 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
THPO P40225 1/20 0.50
CYP4Z1 Q86W10 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
DGAT1 O75907 1/20 0.46
GRM2 Q14416 1/20 0.43
KCNMA1 Q12791 1/20 0.42
MGAM O43451 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30586926 0.79 RAB9A (0.53) RAB9ANPC1SLC9A1MAPTPOLB
SCHEMBL7227104 0.79 SLC9A1 (0.55) RAB9ANPC1SLC9A1MAPTPOLB
SCHEMBL1568148 0.79 RAB9A (0.53) RAB9ANPC1SLC9A1MAPTPOLB
SCHEMBL7100624 0.79 RAB9A (0.53) RAB9ANPC1SLC9A1MAPTPOLB
SCHEMBL221980 0.79 RAB9A (0.53) RAB9ANPC1SLC9A1MAPTPOLB
SCHEMBL24254311 0.76 RAB9A (0.58) RAB9ANPC1SLC9A1MAPTPOLB
SCHEMBL14489533 0.76 RAB9A (0.58) RAB9ANPC1SLC9A1MAPTPOLB
SCHEMBL19111807 0.76 RAB9A (0.58) RAB9ANPC1SLC9A1MAPTPOLB
SCHEMBL7659389 0.76 RAB9A (0.58) RAB9ANPC1SLC9A1MAPTPOLB
SCHEMBL14272188 0.75 SLC9A1 (0.50) RAB9ANPC1SLC9A1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1207161-B1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2006-01-18 EP disclosed
US-6777410-B2 SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-08-17 US disclosed
US-20040053923-A1 Novel isoindole derivatives BANYU PHARMACEUTICAL CO., LTD. 2004-03-18 US disclosed
US-6608098-B1 Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 US disclosed
EP-1207161-A1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053923-A1 Novel isoindole derivatives GPR119, SLC5A2, SLC5A1 RAB9A 965/4885NPC1 451/4885SLC9A1 390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.